Status:
COMPLETED
Phosphoproteomic Patterns as a Novel Biomarker for Aurora and Polo-like Kinase Inhibitors in Non-Small Cell Lung Cancer
Lead Sponsor:
Dartmouth-Hitchcock Medical Center
Conditions:
Non-Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The investigators have characterized in preclinical Non-Small Cell Lung Cancer (NSCLC) models the proteomic expression profile associated with exposure to Aurora and Polo-like kinase inhibitors. The i...
Eligibility Criteria
Inclusion
- Subjects undergoing or who have undergone thoracic surgery for presumed lung cancer
- Wedge resection, lobectomy, bilobectomy, segmentectomy and pneumonectomy thoracic surgical operations are permitted.
- Age ≥ 18 years.
- Subject meets criteria for thoracic surgery as determined by the thoracic surgeon.
- Able to provide written informed consent.
Exclusion
- Subjects undergoing or who have undergone thoracic surgery for metastatic disease from other primary sources such as colorectal cancer, sarcoma, melanoma, breast cancer, bladder cancer, prostate cancer, esophageal cancer, pancreatic cancer, or gastric cancer will be excluded.
- Subjects who have received prior preoperative lung cancer anticancer therapy will be excluded.
Key Trial Info
Start Date :
July 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2020
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT01510405
Start Date
July 1 2010
End Date
April 1 2020
Last Update
August 1 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States, 03756